According to a new research report “Janus Kinase (JAK) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, JAK inhibitors currently exhibits a proliferating pipeline with 45 therapeutic candidates.
JAK Inhibitors Pipeline Insights
JAK comprises four receptors JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) which help in cytokine mediated signaling through the JAK/STAT pathway. There are two nearly identical phosphate transferring domains present in JAKs. The first domain demonstrates kinase activity while the other regulates the activity of the first via negative inhibition. The mutations in the JAK/STAT pathway leads to different medical conditions.
The JAK inhibitors work by blocking the cytokine mediated signaling via JAK/STAT pathway which plays an important role in immune regulation and growth.
The pipeline of JAK inhibitors is quite robust with drugs being developed in the Pre-Registration, Phase III, Phase II, Phase I, Pre-Clinical, and Discovery stage of development. Also, majority of the pipeline products are currently undergoing Phase II clinical studies.
Insights into Pipeline Segments
According to the research findings, majority of the JAK inhibitors in the pipeline are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Moreover, the drugs administered by this route are less invasive and can be modified for extended release, thereby increasing the bioavailability. Also, administration of JAK inhibitors through oral route have shown promising results in the clinical studies.
Positive Clinical Trial Results are Expected to Drive JAK Inhibitors Pipeline Expansion
The companies developing JAK inhibitors have shown positive clinical results in the various phases of drug development. For instance, in January 2018, LEO Pharma A/S’s collaborator Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. announced the topline results from delgocitinib’s Phase III comparative study. The primary endpoints of the study were met and there were no clinically significant findings on safety and tolerability of delgocitinib within the treatment period. Similarly, Astellas Pharma Inc. in February 2018, announced results of two-Phase II trials on peficitinib wherein the drug demonstrated superiority over the placebo w.r.t the primary endpoints. Also, the safety profile of Peficitinib was found to be consistent.
The Global Market of JAK Inhibitors is Expected to Increase Statistically in the next 10 years
A 2018 share analysis done for the three marketed products demonstrated that Jakafi accounts for maximum share in the market, followed by Xeljanz and Olumiant. Therefore, with the emergence of late- and mid-stage pipeline products, the overall JAK inhibitors market is expected to grow significantly in the upcoming years.
Technological Advancements Play a Pivotal Role in the JAK Inhibitors Development
It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of JAK inhibitors. These technologies play an important role in the drug development, thereby helping the companies develop more specific and effective targeted therapies. For instance, the focus of Sienna Biopharmaceuticals Inc.’s Topical by Design Platform is ensuring highly localized drug delivery against the selected targets or pathway, while minimizing the systemic exposure. Highly effective topical therapies are created by utilizing this approach. Moreover, products developed using this technology, if approved, might also be eligible for regulatory exclusivity as new chemical entities (NCEs).
Designation Grants by Regulatory Bodies to Accelerate the Development Process of JAK Inhibitors
A number of drug developers are actively seeking designation grants by the United States Food and Drug Administration (USFDA) and European Medicines Agency (EMA) to accelerate the process of development. For example, Pfizer Inc.’s PF-06700841 and Concert Pharmaceuticals Inc.’s CTP-543 have been granted Breakthrough Therapy Designation and Fast-Track Designation for the treatment of alopecia areata (AA). Since no JAK inhibitor has been approved for dermatologic conditions, Pfizer Inc. and Concert Pharmaceutical Inc. can greatly benefit from this. In addition, Portola Pharmaceuticals Inc., Galapagos NV, and Italfarmaco S.p.A have been granted Orphan Designation for their respective JAK inhibitors.
Browse report overview with detailed TOC on "Janus Kinase (JAK) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/janus-kinase-inhibitors-pipeline-analysis
Strategic Advancements Play a Key Role in the JAK Inhibitors Development
In the wake of various strategic development activities, Theravance Biopharma Inc. and Janssen Global LLC signed an agreement in February 2018 to jointly develop and commercialize Phase I product, TD-1473. Similarly, Galapagos NV and Gilead Sciences Inc. in December 2015 signed a partnership agreement to develop and commercialize filgotinib for the treatment of rheumatoid arthritis and Crohn’s disease. Therefore, collaborating and partnering with other companies can help the current players in the pipeline to expand their drug portfolio for the treatment of diseases related to the JAK/STAT pathway.
Pfizer Inc., Eli Lilly and Company, Incyte Corporation, AbbVie Inc., Concert Pharmaceuticals Inc., Portola Pharmaceuticals Inc., Italfarmaco S.p.A, CTI BioPharma Corp., Theravance Biopharma Inc., Janssen Global LLC, and Galapagos NV are some of the companies involved in the development of JAK inhibitors.
JAK Inhibitors Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed as JAK inhibitors. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the JAK inhibitors development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to JAK inhibitors.